| Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2− p53 interaction K Ding, Y Lu, Z Nikolovska-Coleska, G Wang, S Qiu, S Shangary, W Gao, ... Journal of medicinal chemistry 49 (12), 3432-3435, 2006 | 837 | 2006 |
| Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition S Shangary, D Qin, D McEachern, M Liu, RS Miller, S Qiu, ... Proceedings of the National Academy of Sciences 105 (10), 3933-3938, 2008 | 816 | 2008 |
| Structure-based design of potent non-peptide MDM2 inhibitors K Ding, Y Lu, Z Nikolovska-Coleska, S Qiu, Y Ding, W Gao, J Stuckey, ... Journal of the American Chemical Society 127 (29), 10130-10131, 2005 | 769 | 2005 |
| Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-κB pathway and generation of reactive oxygen species Y Jin, Z Lu, K Ding, J Li, X Du, C Chen, X Sun, Y Wu, J Zhou, J Pan Cancer research 70 (6), 2516-2527, 2010 | 345 | 2010 |
| Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway X Ren, L Duan, Q He, Z Zhang, Y Zhou, D Wu, J Pan, D Pei, K Ding ACS medicinal chemistry letters 1 (9), 454-459, 2010 | 246 | 2010 |
| Quantitative, wide-spectrum kinase profiling in live cells for assessing the effect of cellular ATP on target engagement JD Vasta, CR Corona, J Wilkinson, CA Zimprich, JR Hartnett, MR Ingold, ... Cell chemical biology 25 (2), 206-214. e11, 2018 | 219 | 2018 |
| Potent and orally active small-molecule inhibitors of the MDM2− p53 interaction S Yu, D Qin, S Shangary, J Chen, G Wang, K Ding, D McEachern, S Qiu, ... Journal of medicinal chemistry 52 (24), 7970-7973, 2009 | 217 | 2009 |
| Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia CP Guise, AM Mowday, A Ashoorzadeh, R Yuan, WH Lin, DH Wu, ... Chinese journal of cancer 33 (2), 80, 2014 | 202 | 2014 |
| Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1 X Hui, H Li, Z Zhou, KSL Lam, Y Xiao, D Wu, K Ding, Y Wang, ... Journal of Biological Chemistry 285 (14), 10273-10280, 2010 | 194 | 2010 |
| Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma C Ambrogio, G Gomez-Lopez, M Falcone, A Vidal, E Nadal, N Crosetto, ... Nature medicine 22 (3), 270-277, 2016 | 187 | 2016 |
| Design, Synthesis, and in Vitro Biological Evaluation of 1H-1,2,3-Triazole-4-carboxamide Derivatives as New Anti-influenza A Agents Targeting Virus Nucleoprotein H Cheng, J Wan, MI Lin, Y Liu, X Lu, J Liu, Y Xu, J Chen, Z Tu, ... Journal of medicinal chemistry 55 (5), 2144-2153, 2012 | 176 | 2012 |
| BMPs functionally replace Klf4 and support efficient reprogramming of mouse fibroblasts by Oct4 alone J Chen, J Liu, J Yang, Y Chen, J Chen, S Ni, H Song, L Zeng, K Ding, ... Cell research 21 (1), 205-212, 2011 | 164 | 2011 |
| Discovery and Optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as Novel Selective and Orally Bioavailable Discoidin Domain Receptor 1 … M Gao, L Duan, J Luo, L Zhang, X Lu, Y Zhang, Z Zhang, Z Tu, Y Xu, ... Journal of medicinal chemistry 56 (8), 3281-3295, 2013 | 154 | 2013 |
| (2-Pyridyl) acetone-promoted Cu-catalyzed O-arylation of phenols with aryl iodides, bromides, and chlorides Q Zhang, D Wang, X Wang, K Ding The Journal of Organic Chemistry 74 (18), 7187-7190, 2009 | 154 | 2009 |
| Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells JX Pan, K Ding, CY Wang Chinese journal of cancer 31 (4), 178, 2012 | 150 | 2012 |
| Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region–abelson (Bcr-Abl) kinase and overcomes … X Ren, X Pan, Z Zhang, D Wang, X Lu, Y Li, D Wen, H Long, J Luo, ... Journal of medicinal chemistry 56 (3), 879-894, 2013 | 142 | 2013 |
| Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry X Lu, L Yu, Z Zhang, X Ren, JB Smaill, K Ding Medicinal research reviews 38 (5), 1550-1581, 2018 | 138 | 2018 |
| Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790→ methionine790 mutant S Chang, L Zhang, S Xu, J Luo, X Lu, Z Zhang, T Xu, Y Liu, Z Tu, Y Xu, ... Journal of Medicinal Chemistry 55 (6), 2711-2723, 2012 | 138 | 2012 |
| An Efficient Copper‐Catalyzed Amination of Aryl Halides by Aqueous Ammonia D Wang, Q Cai, K Ding Advanced Synthesis & Catalysis 351 (11‐12), 1722-1726, 2009 | 137 | 2009 |
| Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer S Shangary, K Ding, S Qiu, Z Nikolovska-Coleska, JA Bauer, M Liu, ... Molecular cancer therapeutics 7 (6), 1533-1542, 2008 | 128 | 2008 |
